5,6,7,8-Tetrahydro-chinolin-3-carboxamid | 99068-05-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5,6,7,8-Tetrahydro-chinolin-3-carboxamid
• 英文别名: 5,6,7,8-tetrahydro-quinoline-3-carboxylic acid amide；5,6,7,8-Tetrahydroquinoline-3-carboxamide
• CAS: 99068-05-0
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: IFDSRBCGFYEBLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Quinoline derivative
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10208022B2

  公开（公告）日：2019-02-19

  A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases

  通式(I)代表的化合物通过引入饱和碳环与吡啶酮环融合的独特双环结构，具有很强的 Axl 抑制活性，可作为 Axl 相关疾病的治疗剂，例如急性髓性白血病、黑色素瘤、乳腺癌、胰腺癌和胶质瘤等癌症、肾脏疾病、免疫系统疾病和循环系统疾病的治疗剂。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3203840A1

  公开（公告）日：2017-08-16
• QUINOLINE DERIVATIVE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20180258072A1

  公开（公告）日：2018-09-13

  A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases
• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE
  申请人：MILLER MARK THOMAS

  公开号：WO2016057572A1

  公开（公告）日：2016-04-14

  The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.